比较家庭血液透析与肾移植受者生存的多中心注册分析
该研究利用澳大利亚和新西兰透析与移植注册数据,纳入1997至2017年起始90天内的家庭血液透析患者和首次肾移植受者。结果显示,活体供肾和标准标准供肾受者死亡风险低于家庭血透患者,但扩大标准供肾受者与家庭血透患者死亡风险相当;所有移植受者的治疗失败或死亡复合终点均优于家庭血透。
要点
- 活体供肾和标准标准供肾受者死亡风险低于家庭血透患者。
- 扩大标准供肾受者与家庭血透患者死亡风险相当。
- 所有移植受者治疗失败或死亡复合终点均优于家庭血透。
核心结论
- 肾移植相比家庭血透提供生存获益,但该优势对扩大标准供肾受者不显著。
研究设计与样本
- 基于澳大利亚和新西兰透析与移植注册的前瞻性队列研究,纳入1997至2017年起始90天内的家庭血透患者和首次肾移植受者。
主要发现
- 活体供肾受者死亡风险低于家庭血透患者(调整HR=0.57,95%CI 0.46-0.71)。
- 标准标准供肾受者死亡风险低于家庭血透患者(调整HR=0.65,95%CI 0.52-0.79)。
- 扩大标准供肾受者与家庭血透患者死亡风险相当(HR=0.90,95%CI 0.73-1.12)。
- 活体供肾、标准标准供肾和扩大标准供肾受者的治疗失败或死亡复合终点均优于家庭血透患者。
临床怎么用
- 在器官短缺背景下,家庭血透可作为等待肾移植的桥接治疗。
- 扩大标准供肾移植的生存获益与家庭血透相当,决策时需综合评估。
局限性
- 注册研究可能存在未测量混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the era of organ shortage, home hemodialysis (HHD) has been identified as the possible preferential bridge to kidney transplantation. Data are conflicting regarding the comparability of HHD and transplantation outcomes. This study aimed to compare patient and treatment survival between HHD patients and kidney transplant recipients. METHODS: The Australia and New Zealand Dialysis and Transplant Registry was used to include incident HHD patients on Day 90 after initiation of kidney replacement therapy and first kidney-only transplant recipients in Australia and New Zealand from 1997 to 2017. Survival times were analyzed using the Kaplan-Meier product-limit method comparing HHD patients with subtypes of kidney transplant recipients using the log-rank test. Adjusted analyses were performed with multivariable Cox proportional hazards regression models for time to all-cause mortality. Time-to-treatment failure or death was assessed as a composite secondary outcome. RESULTS: The study compared 1411 HHD patients with 4960 living donor (LD) recipients, 6019 standard criteria donor (SCD) recipients and 2427 expanded criteria donor (ECD) recipients. While LD and SCD recipients had reduced risks of mortality compared with HHD patients [LD adjusted hazard ratio (HR) = 0.57, 95% confidence interval (CI) 0.46-0.71; SCD HR = 0.65 95% CI 0.52-0.79], the risk of mortality was comparable between ECD recipients and HHD patients (HR = 0.90, 95% CI 0.73-1.12). LD, SCD and ECD kidney recipients each experienced superior time-to-treatment failure or death compared with HHD patients. CONCLUSIONS: This large registry study showed that kidney transplant offers a survival benefit compared with HHD but that this advantage is not significant for ECD recipients.
引用
- Ethier I, Cho Y, Hawley C, et al. Multicenter registry analysis comparing survival on home hemodialysis and kidney transplant recipients in Australia and New Zealand. Nephrol Dial Transplant. 2021. PMID: 32879952. doi:10.1093/ndt/gfaa159
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。